Entity

Time filter

Source Type

Singapore, Singapore

Biomax Informatics is a Munich-based software company specializing in research software for bioinformatics. Biomax was founded in 1997 and has its roots in the Munich Information Center for Protein Sequences . The company's customer base consists of companies and research organizations in the areas of drug discovery, diagnostics, fine chemicals, food and plant production. In addition to exclusive software tools, Biomax Informatics provides services and curated knowledge bases.In September 2007, Biomax Informatics acquired the Viscovery software business of the Austrian data mining specialist Eudaptics Software.Biomax Informatics and Sophic Systems Alliance Inc. participate in the Cancer Gene Data Curation Project with the National Cancer Institute . This project maintains a public data set of cancer-related genes and drugs. This data set has been integrated with the NCI's caBIO domain model which is part of the CaBIG Integrative Cancer Research workspace. This Cancer Gene Index can be obtained separately from an NCI web site. Wikipedia.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2013.2.3.3-1 | Award Amount: 31.38M | Year: 2014

Far from receding, the threats posed by infections with epidemic potential grow ever greater. Although Europe has amongst the best healthcare systems in the world, and also the worlds supreme researchers in this field, we lack co-ordination and linkage between networks that is required to respond fast to new threats. This consortium of consortia will streamline our response, using primary and secondary healthcare to detect cases with pandemic potential and to activate dynamic rapid investigation teams that will deploy shared resources across Europe to mitigate the impact of future pandemics on European health, infrastructure and economic integrity. If funded, PREPARE will transform Europes response to future severe epidemics or pandemics by providing infrastructure, co-ordination and integration of existing clinical research networks, both in community and hospital settings. It represents a new model of collaboration and will provide a one-stop shop for policy makers, public health agencies, regulators and funders of research into pathogens with epidemic potential. It will do this by mounting interepidemic (peace time) patient oriented clinical trials in children and in adults, investigations of the pathogenesis of relevant infectious diseases and facilitate the development of sophisticated state-of-the-art near-patient diagnostics. We will develop pre-emptive solutions to ethical, administrative, regulatory and logistical bottlenecks that prevent a rapid response in the face of new threats. We will provide education and training not only to the members of the network, but also to external opinion leaders, funders and policy makers thereby streamlining our future response. By strengthening and integrating interepidemic research networks, PREPARE will enable the rapid coordinated deployment of Europes elite clinical investigators, resulting in a highly effective response to future outbreaks based on solid scientific advances.


Patent
BioMax | Date: 2011-03-23

The present invention relates to a process for treating organic waste, which comprises the step of contacting an organic waste with one or more microorganisms from at least three of the following microorganism species:


Patent
BioMax | Date: 2014-05-05

The present invention relates to a process for treating organic waste, which comprises the step of contacting an organic waste with one or more microorganisms from at least three of the following microorganism species:


Grant
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2010.2.4.5-1 | Award Amount: 15.66M | Year: 2010

Causes explaining the epidemic of IgE-associated (allergic) diseases are unclear. MeDALL (Mechanisms of the Development of Allergy) aims at generating novel knowledge on mechanisms of allergy initiation, in particular in childhood. To understand how a complex network of genetic and environmental factors leads to complex allergic phenotypes, a novel stepwise, large and integrative translational approach is needed. MeDALL includes experts in allergy, epidemiology, genetics, immunology, biology, animal models, biochemistry and systems biology combining strengths of ongoing EU projects. Classical phenotypes (expert-based) and novel phenotypes of allergy (hypothesis-free statistical modelling) are compared. Population-based data are collected from a cross-sectional study (Karelia) and existing birth-cohorts followed using a common protocol. IgE to foods and inhalants are tested using component-resolved diagnosis across Europe in populations. Biomarker profiles (fingerprints) are extensively assessed using epigenetics, targeted proteomics and unbiased transcriptomics in a subsample of the study population. Those associated with allergic phenotypes are validated in large study populations. Relevant fingerprints are combined into network biomarker phenotype handprints using a systems biology approach and validated in a sufficiently powered sample. Animal studies and in vitro human immunology reinforce the validation. This information coupled with classical and novel phenotypes characterize environmental protective and susceptibility factors of allergy and risk groups. Results are fitted into new integrative complex mathematical models to establish suitable biomarkers for early diagnosis, prevention and targets for therapy of allergy-associated diseases such as asthma and atopic dermatitis. Ethics and gender are considered. MeDALL aims at improving health of European citizens, Europe competitiveness and innovative capacity while addressing global health issues.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.2.1-2 | Award Amount: 6.32M | Year: 2013

The theme of this collaborative project is development and application of neuroimaging and bioinformatics tools to study lipid metabolism as a common pathogenic link between psychotic disorders and its metabolic co-morbidities. The overall objective is to identify, prioritize and evaluate multi-modal blood and neuroimaging markers with diagnostic potential for prediction and monitoring of psychotic disorders and associated metabolic co-morbidities. We aim to (1) optimise a multidisciplinary approach for combining positron emission tomography (PET) and magnetic resonance imaging (MRI) with metabolomics approaches, (2) develop a PET-method for exploring endocannabinoid pathways in early psychosis in longitudinal study setting, and (3) develop combined PET-MRI biomarker methodology for psychiatric disorders by studying neurotransmitter interactions with multiple PET scan and MRI sequences. The balance of two or more neurotransmitter systems may function as a novel biomarker in these disorders. The expected impacts are (1) etiopathogenic understanding, (2) new validated multi-modal markers for early disease detection and monitoring, (3) new tools for the identification of subjects who may benefit from specific treatment (4) discovery of new avenues for disease prevention and therapy, and (5) new tools and processes for applying brain imaging in personalised medicine. The consortium brings together clinicians, researchers and industry partners in the domains of psychiatry, neuroimaging, metabolic research, systems biology and bioinformatics.

Discover hidden collaborations